HIGHMARK WHOLECARE

Updated: 06/2024
PARP Approved: 06/2024

Prior Authorization Criteria
Synagis (palivizumab)

All requests for Synagis (palivizumab) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a diagnosis of prevention of Respiratory Syncytial Virus (RSV) and the following criteria is met:

- Must have a documented reason for not being able to use Beyfortus (nirsevimab-alip)

- Member must not have received Beyfortus (nirsevimab-alip) for the current respiratory syncytial virus (RSV) season

- The member must be a pediatric member determined to be at high-risk for RSV.
    - High Risk is considered one of the following:

        - Infants < 29 weeks, 0 days gestational at birth and < 12 months of age on the start of the RSV season

        - Infants with Chronic Lung Disease of prematurity, defined as having been < 32 weeks, 0 days gestational at birth, and < 12 months of age on the start of the RSV season with a > 21% oxygen requirement for at least 28 days after birth

        - Infants < 12 months of age on the start of the RSV season with a congenital abnormality of the airway or neuromuscular condition that compromises respiratory secretion clearance

        - Infants < 12 months of age on the start of the RSV season and diagnosed with hemodynamically significant Congenital Heart Disease (i.e. receiving medications to control HF and will require cardiac surgical procedures or with moderate to severe pulmonary hypertension or with acyanotic heart disease or with cyanotic heart disease when a cardiologist has been consulted)

        - Infants < 12 months of age on the start of the RSV season with Cystic Fibrosis and clinical evidence of Chronic Lung Disease (CLD) requiring medical therapy or nutritional compromise as per the AAP guidelines

- Infants < 2 years of age at the time of request who had CLD of prematurity and has continued to require medical therapy (supplemental oxygen, bronchodilator, diuretic, or corticosteroid therapy) for CLD within the past 6 months

- Infants < 2 years of age at the time of request with CHD and who have received a heart transplant during the RSV season

- Infants < 2 years of age at the time of request and are profoundly immunocompromised as defined by receiving chemotherapy or received an organ or stem cell transplant

- Infants < 2 years of age at the time of request with Cystic Fibrosis and with risk factors as per the AAP guidelines (i.e. weight for length < 10th percentile, abnormalities on chest radiography or chest computed tomography that persist when stable, previous hospitalization for pulmonary exacerbation in the first year of life)

Initial Duration of Approval: A 5 month maximum duration with an authorization not to exceed March 31st. Requests for additional doses outside of the typical RSV season will be reviewed on a case-by-case basis based on CDC surveillance reports, state/local health department recommendations, and other current medical literature.

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

HIGHMARK WHOLECARE

Updated: 06/2024
PARP Approved: 06/2024

SYNAGIS (PALIVISUMAB)
PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Wholecare Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (800) 392-1147 Mon – Fri 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	Provider NPI:
Provider Specialty:	Office Contact:
State license #:	Office NPI:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? ☐ Yes ☐ No	Date Medication Initiated:	

Billing Information

This medication will be billed: ☐ at a pharmacy **OR** ☐ medically, JCODE:_____

Place of Service: ☐ Hospital ☐ Provider's office ☐ Member's home ☐ Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Primary Diagnosis:	ICD Code:
Additional Diagnosis	ICD Code

(additional diagnosis and supporting documentation is required for any child over 29 weeks)

Has the member received Beyfortus (nirsevimab-alip) for the current RSV season? ☐ No ☐ Yes

If the member is has not received Beyfortus please provide documentation of why the member has not or is unable to.

Was the first dose administered in the hospital? ☐ No ☐ Yes (date administered)_____

(dose administered)_____

Is the member's age 12 months of age or less as of start of RSV season: ☐ No ☐ Yes

Does the member have hemodynamically significant heart disease? ☐ No ☐ Yes

Has or will the member require a cardiac surgical procedure? ☐ No ☐ Yes

Procedure:_____ Date of procedure:_____

Has a cardiologist been consulted? ☐ No ☐ Yes (please provide consultation recommendation)

☐ Moderate to severe pulmonary hypertension:

HIGHMARK WHOLECARE

Updated: 06/2024
PARP Approved: 06/2024

SYNAGIS (PALIVISUMAB)
PRIOR AUTHORIZATION FORM (CONTINUED)– PAGE 2 of 2

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Wholecare Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (800) 392-1147 Mon – Fri 8:30am to 5:00pm

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

MEDICAL HISTORY (Complete for ALL requests)

☐ Acyanotic heart disease. Diagnosis:_____

☐ Cyanotic heart disease: Diagnosis:_____

☐ Receiving medications to control CHF. Provide medications, dose, and dates of administration below:

_____

Does the member have chronic lung disease? ☐ No ☐ Yes

Was oxygen required at birth? ☐ No ☐ Yes Provide percentage: _____Provide duration:_____

Were medications used to treat chronic lung disease in the past 6 months? ☐ No ☐ Yes (provide detail below)

☐ Supplemental O2: _____

☐ Bronchodilator(s): _____

☐ Diuretic(s): _____

☐ Corticosteroid(s): _____

Additional risk factors: Please check all that apply and provide requested information on space provided.

☐ Compromised respiratory secretion clearance due to:

☐ Congenital abnormality of the airway. Diagnosis: _____

☐ Neuromuscular condition. Diagnosis: _____

☐ Profoundly immunocompromised. Diagnosis:_____

☐ Receiving chemotherapy. Provide therapy regimen:_____

☐ Received organ or stem cell transplant. Provide procedure date_____

☐ Cystic fibrosis and clinical evidence of Chronic Lung Disease requiring medical therapy or nutritional compromise as per the AAP guidelines. Submit supporting documentation.

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature	Date